glp-1 based therapeutics summit CenExel is attending the in Boston this April. Kimball A. Johnson, M.D., Chief Medical Director (Symposium/Eng) GLP-1 Therapeutics

In January 2025, the FDA approved an injectable form of semaglutide (Ozempic) specifically for managing chronic kidney disease in type 2 diabetes patients

We believe this system provides a foundation for gene- and cell-based therapeutic applications that require once-daily therapeutic dosing

Nutritional regulation of glucagon-like peptide-1 secretion

People who may benefit from resM Those who do not qualify for prescription GLP-1 medications

For individuals with metabolic disorders or hormonal imbalances that make losing weight particularly difficult, weight loss injections provide a science-backed solution

12,13 As the incidence of IIH is rising 1416 in line with global obesity trends, 17 targeted treatments are an unmet clinical need